Literature DB >> 22178120

Developing treatments for impaired cognition in schizophrenia.

Michael J Minzenberg1, Cameron S Carter.   

Abstract

Schizophrenia is one of the most debilitating of all common brain disorders, exacting a heavy toll on the afflicted and having a tremendous public health impact. Clinical outcome is more strongly predicted by cognitive deficits than psychotic symptoms, with no established treatment for these deficits. In this review, we discuss the status of treatment development for impaired cognition in schizophrenia. These treatments include a range of pharmacological targets within diverse neurotransmitter systems. New technologies, including transcranial magnetic stimulation and transcranial direct current stimulation, and psychological therapies, such as computer-based cognitive training, may also benefit cognition in schizophrenia. Each of these approaches shows promise and their integration may optimize benefits for patients in the future.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178120     DOI: 10.1016/j.tics.2011.11.017

Source DB:  PubMed          Journal:  Trends Cogn Sci        ISSN: 1364-6613            Impact factor:   20.229


  40 in total

Review 1.  Cognition in schizophrenia: core psychological and neural mechanisms.

Authors:  Deanna M Barch; Alan Ceaser
Journal:  Trends Cogn Sci       Date:  2011-12-12       Impact factor: 20.229

2.  External Excitation of Neurons Using Electric and Magnetic Fields in One- and Two-dimensional Cultures.

Authors:  Shani Stern; Assaf Rotem; Yuri Burnishev; Eyal Weinreb; Elisha Moses
Journal:  J Vis Exp       Date:  2017-05-07       Impact factor: 1.355

Review 3.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

4.  Cognition in schizophrenia: Past, present, and future.

Authors:  Michael F Green; Philip D Harvey
Journal:  Schizophr Res Cogn       Date:  2014-03

5.  The mediating effect of family cohesion in reducing patient symptoms and family distress in a culturally informed family therapy for schizophrenia: A parallel-process latent-growth model.

Authors:  Caitlin A Brown; Amy Weisman de Mamani
Journal:  J Consult Clin Psychol       Date:  2017-11-27

6.  Gamma rhythms link prefrontal interneuron dysfunction with cognitive inflexibility in Dlx5/6(+/-) mice.

Authors:  Kathleen K A Cho; Renee Hoch; Anthony T Lee; Tosha Patel; John L R Rubenstein; Vikaas S Sohal
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

7.  Contributions of Feature Binding During Encoding and Functional Connectivity of the Medial Temporal Lobe Structures to Episodic Memory Deficits Across the Prodromal and First-Episode Phases of Schizophrenia.

Authors:  Kristen M Haut; Theo G M van Erp; Barbara Knowlton; Carrie E Bearden; Kenneth Subotnik; Joseph Ventura; Keith H Nuechterlein; Tyrone D Cannon
Journal:  Clin Psychol Sci       Date:  2015-03

8.  Roles of Prefrontal Cortex and Mediodorsal Thalamus in Task Engagement and Behavioral Flexibility.

Authors:  Tobias F Marton; Helia Seifikar; Francisco J Luongo; Anthony T Lee; Vikaas S Sohal
Journal:  J Neurosci       Date:  2018-02-07       Impact factor: 6.167

9.  Probabilistic Category Learning and Striatal Functional Activation in Psychosis Risk.

Authors:  Nicole R Karcher; Jessica P Y Hua; John G Kerns
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

10.  Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.

Authors:  Michael J Minzenberg; Jong H Yoon; Yaoan Cheng; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2015-09-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.